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Patients with Highly Invasive Cutaneous Melanoma
Need Selective, Focused Evaluations Before Surgery
Perhaps President Reagan's experience with basal cell carcinoma will
keep a few more palefaces out of the
sun. The same caution-to stay away
from UV light, although that is only
one suspected cause-applies to cutaneous melanoma, the skin cancer
that is more invasive, more difficult
to control, and rising in incidence at
a faster rate than almost any other
cancer.
Although the occurrence of cuta- Charles M. Balch
neous melanoma is doubling every
six to 10 years, the natural history of the disease has become
somewhat less threatening in the last two decades, typical melanomas being thinner, less invasive, and therefore more curable.
A national survey of more than 4,500 melanoma patients treated
during 1980 demonstrated that 87% of patients had clinically
localized-that is, early-disease. In 39% of these patients, the
melanomas were less than 0. 76 mm thick, a size associated with a
90% or higher rate of cure.
As Charles M. Balch, M.D., head of the Division of Surgery at
UT MDAH, noted, "The natural history of this disease has
changed dramatically and so must our treatment strategies and
diagnostic approaches."
Balch described the usual patient with melanoma as a man or
woman with a fair complexion and a tendency to sunburn after
relatively brief exposure to bright sunlight. A patient with melanoma has a 3 % to 5% risk of developing a second primary melanoma and thus joins a "high-risk group of patients who should be
followed for metastatic disease and second primary tumors."
Patients with familial melanomas or with the dysplastic nevus
syndrome are identifiable high-risk groups, Balch wrote in
reviewing the clinical management of cutaneous melanoma in
Texas Medicine (83:70-78, 1987).
Balch advised physicians to obtain biopsies whenever they see
subtle changes in any pigmented skin lesion, which may include
growth in diameter or contour of a mole, change in color, bleeding, itching, ulceration, development of a palpable lymph node,
or a combination of these. A melanoma's features are "usually
more subtle when it is in a more curable stage," he wrote.
As to metastatic melanoma, no other cancer in humans has as
variable a history because melanoma may spread to virtually any

organ or tissue. But there are patterns. The regional lymph nodes
are the most common sites of metastasis, and the most common
first sites of distant metastasis are skin, subcutaneous tissue, and
lung. Liver , bone, and brain are common sites of first relapse,
Balch wrote.

Selective Tests
Instead of a broadside of tests, patients should at first undergo
careful history-taking and physical examination, Balch advised.
More expensive radiologic or nuclear scans are not indicated, he
said, unless there are signs or symptoms suggestive of metastatic
disease as discovered by a simple, cost-effective series of screening
exams. The metastatic survey should be selective:
• Chest roentgenogram for lung metastasis, which may be suspected but usually has no symptoms-confirmed, if necessary,
by lung tomograms or CT scan.
• Serum alkaline phosphatase and lactic dehydrogenase assays
and examination for liver mass or ascites in the case of liver
symptoms of weight loss, anorexia, and upper abdominal
pain-followed by liver sonar or abdominal CT scan if
indicated.
• Physical examination in the case of suspected subcutaneous or
skin metastasis or second primary melanomas-followed by

biopsy examination.
• Complete history and physical examination for brain symptoms of headache, numbness, motor weakness, followed by
brain CT scan if indicated.
• Alkaline phosphatase assay for localized pain of bone metastasis, and then bone scan and bone X-ray for confirmation.
• Urinalysis for hematuria indicating kidney or bladder metastasis, and then intravenous pyelogram or cytoscopic examination
or both if indicated.

Surgical Management
Primary melanomas are removed by wide excision, except for
lentigo maligna melanomas, which have a low recurrence rate

continued on page 2
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and do not need wide surgical margins. Overall, the primary melanomas have a recurrence rate of only about 3%, although
tumors with a thickness of 4 mm or more, ulceration, or location
on foot, hand, scalp, or face have higher rates oflocal recurrence.
Metastasis occurs most frequently in the regional lymph
nodes, and it will be clinically evident from enlarged, firm, nontender nodes or be hidden as microscopic metastases in lymph
nodes, Balch explained.
In patients with clinically enlarged nodal metastases, the treatment is radical lymphadenectomy because partial lymph node
dissection or simple excision is inadequate. "Since the surgeon's
ability to detect nodal metastases by clinical criteria is not optimal," Balch noted, "a philosophy oflimited excision for only clinically detectable nodes will often compromise both the palliative
and curative goals of surgical treatment."
Management of suspected microscopic metastases in the
regional lymph nodes is more difficult, he explained, because the
central question concerns the optimal timing of surgery. The
procedure can be done immediately to remove any suspected

tumor, especially an intermediate-thickness melanoma measuring up to 4 mm, or it can be delayed until nodal metastases are
large enough to be detected by-palpat ion.
After presenting all sides of the argument for early or for later
surgical intervention, Balch noted that, since the cure rate for
delayed lymph node dissection is so poor-25% survival at 10
years-"ma ny surgeons advocate immediate excision of the
regional lymph n odes in selected patients to remove nodal micrometastases before they can disseminate. In this setting, surgical
decisions depend on knowing which prognostic factors can reliably identify patients at risk for occult metastatic disease."
Balch is now principal investigator of a surgical trial that will
involve more than 800 patients in 57 institution s in the United
States and Canada and address issues of the most appropriate
extent and timing of surgical intervention. More than 500
patients are already participating in the study.
Balch noted that, unfortunately, adjuvant therapy for regional
metastasis of cutaneous melanoma, including immunotherapy,
chemotherapy, and radiation therapy, have not been notably
successful after operations. This underscores the need for regular
follow-up examinations-every three to four months for the first
two years, every six months through the fifth year, and yearly
thereafter-to examine these patients for recurrent disease.

Distant Metastasis
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For patients who have advanced melanoma, Balch explained,
treatment depends on site and number of lesions, rate of growth,
previous treatment, and the patient's age, overall condition, and
wishes. Balch stressed consideration of the benefit-risk ratio of
treatment intended to relieve the patient's symptoms, saying
that the benefit-risk balance must be even stronger in the case of
asymptomatic patients with distant metastases. Treatment
choices include no treatment; surgical excision of the melanoma
for palliative effect, which may be sustained for three to five years
in some cases; palliative radiotherapy, which Balch said is effective for superficial metastatic disease of the skin or soft tissues
where lesions can be treated with high-energy photon beams
from a linear accelerator; chemotherapy and immunotherapy,
which have their greatest potential benefit in patients with
symptomatic visceral disease.
Dacarbazine (DTIC), Balch pointed out, is the only drug currently available that has had significant activity in melanoma,
most studies having shown 15% to 20% response rates. "Often,"
Balch said, "chemotherapy is used only in patients whose lesions
are not amenable to surgery or radiation therapy, and only sparingly in asymptomatic patients."

Physicians who desire additional information may write Charles M.
Balch, M.D., Division of Surgery, Box 112, The University of Texas
M . D. Anderson Hospital and Tumor Institute at Houston 1515
Holcombe Boulevard, Houston, Texas 77030.
'
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Adjuvant Chetnotherapy ltnproves Survival of
Patients with Stage II and III Breast Cancer
The overall survival for breast cancer patients has improved in the last
decade. According to Aman Buzdar,
M.D., of the Medical Breast Unit at
UT M. D. Anderson Hospital and
Tumor Institute (UT MDAH), great
progress has been made, especially
for patients with stage II and III disease, thanks to the development of
more aggressive adjuvant chemotherapy regimens. In addition, modest gains have been made in patients Aman u Buzdar
with disseminated disease. Buzdar,
along with his colleagues at UT MDAH and other institutions,
has been involved in several studies examining the effect on
patient survival of alternating the drugs in a chemotherapy regimen, administering higher doses of drugs over a shorter period of
time, and matching chemotherapy to certain pathologic prognostic factors of the patient.
According to Buzdar, the most aggressive chemotherapy regimen used to date is the combination of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC), with doxorubicin being the most active agent of the combination. Studies in
breast cancer treatment are currently evaluating ways to improve the effectiveness of this regimen and seem to be meeting
with success.

Combination Chemotherapy

patients in the 1950s. Although there were possible biases inherent in the study, the results showed that patients treated in the
1970s had an improvement in median survival of 9 to 12 months
compared with patients treated in the previous two decades (see
Fig. 1). Buzdar and his colleagues concluded that combination
chemotherapy, though not significantly affecting mortality rates,
definitely prolonged the survival of breast cancer patients.
Recent studies show that median follow-up of patients treated
in the late 1970s was 28-32 months, suggesting continued
improvement in median survival for patients with metastatic disease. While there is currently only a slight potential for cure,
Buzdar says "long-term unmaintained remissions do occur
in about 3-4% of the patients with metastatic disease. We are
keeping patients alive much longer with chemotherapies than
we did 8-10 years ago."
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Fig. 1. Overall comparison
of survival by decades. From
M.B. Ross, A.U. Buzdar, T. L.
Smith, et al. Cancer 1985;
55:341-346. Reprinted with
permission .

lr0

~ .40

.20

.00

24

48

72

96

MONTHS

Combination chemotherapy for the treatment of metastatic
breast cancer has been proved effective in several studies conducted by a diverse group of researchers. In 1985 Buzdar, along
with Michael Ross, M.D., and their colleagues, published the
results of a retrospective study that compared survival of patients
with metastatic breast cancer for three decades: the 1950s, 1960s,
and 1970s. The aim of the study was to determine if the use of
combination chemotherap')' in the 19 Os had an im act on survival in patients with evidence of metastatic disease. Most of the
patients in the 19 50s and the 1960s were treated with singleagent chemotherapy, endocrine therapies, or both; by the 1960s,
most were receiving single-agent chemotherapy. Patients in the
1970s were predominantly treated with combination chemotherapy regimens that usually included doxorubicin.
The median survival time was 22 months for patients in the
1970s and 12 months for patients in the 1960s; patients in the
1960s did not have a significantly longer survival time than
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Adjuvant Chemotherapy Trials

Research has shown that the most effective use of chemotherapy in high-risk patients (patients with stage II and III disease) is
as an adjuvant to primary local treatments (surgery and irradiation). In 1986, Buzdar and his colleagues published the results
-f- a- tcen-year- aafl::l.-v-a-nt--€-hemer--her-ary---+F-i-a-1- feF-eFe-ast- E-anG@-I"- patients. Beginning in 1974, patients with stage II and III disease
received FAC chemotherapy after mastectomy (and in some
cases after postoperative irradiation). The five-year survival for
the study group was compared with the five-year survival for a
consecutive series of patients with stage II and III disease seen at
UT MDAH two years immediately preceding the initiation of
the FAC trial (historical control group). The historical control

continued on page 4
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group did not receive systemic therapy following regional therapy
until there was evidence of disease recurrence.
The data for this ten-year follow-up trial clearly show that
adjuvant chemotherapy (FAC combinations) was effective in
reducing mortality in high-risk patients. In patients 50 years of
age, the FAC combination was effective in reducing the mortality
by 54% ; in patients older than 50, the reduction in mortality was
37% . (See Table 1 for a comparison of estimated disease-free survival rates for the study and control groups.)
Subsequent prospective adjuvant FAC chemotherapy trials
have also highlighted the relative ineffectiveness of postoperative
irradiation and nonspecific immunotherapy with bacille
Calmette-Guerin (BCG) and have confirmed the effectiveness of
FAC regimens in improving patients' survival. NIH consensus
data make it clear that tamoxifen has not been effective in reducing mortality in patients younger than 50 regardless of estrogen
receptor (ER) status. In patients who were older than 50 and ER
positive, however, the use of tamoxifen reduced mortality at 5
years by 19%.

positive or unknown status were randomized to receive either
tamoxifen alone for 6 months or tamoxifen and additional chemotherapy with methotrexate and vinblastine (TMV), which
constituted a year of chemotherapy. All ER-negative patients
received 6 months of additional chemotherapy with methotrexate and vinblastine (MV).
Patients with ER-positive tumors who received alternative chemotherapy with additional drugs (TMV) had a lower risk of
recurrence than patients who received tamoxifen followi ng t he
initial chemotherapy phase; the difference in recurrence rate was
not significant, however, when patients whose ER status was
unknown were included in the analysis. ER-positive patients
treated with additional alternate chemotherapy had superior
disease-free survival compared with patients who received
tamoxifen after completion of the FAC regimen .
Patients with ER-negative disease treated with additional chemotherapy had lower disease-free survival rates than those who
had ER-positive disease. Buzdar notes that the addition of vincristine and prednisone to the FAC combination did not
enhance the therapeutic efficacy of the regimen. A summary of
estimated disease-free survival at 5 years for patients in this study
is shown in Table 2.

Alternate Drugs and Shorter Therapy

TABLE2

Researchers at UT MDAH have also examined the role of
shorter-duration combination chemotherapy in their patients.
"We used to continue chemotherapy for two years," says Buzdar,
who with his colleagues at UT MDAH started an adjuvant chemotherapy trial in 1980 that addressed the issues of shorter treatment time and alternate drug combinations. It was their hope
that the patient's survival could be improved by making the
duration of treatment shorter and more intense and by altering
the combination after a certain length of time. In the study
(which has recently been completed with a five-year follow-up),
vincristine and prednisone were added to the FAC therapy of
patients with stage 11 and Ill disease; the patients received this
chemotherapy for 6 months, after which all patients with ERTABLE 1
Comparison of Estimated Disease-Free Survival and Survival
Rates at 10 Years in First Study and Control Group

Group

Treatment

Patients

Percent
Disease-Free

p

Percent
Alive

p*

All pts

FAC
Control

222
186

49
33

<.01
<.01

55
34

<.01
<.01

Stage II

FAC
Control

147
116

55
36

<.01
< .01

63
38

<.01
<.01

Stage llI

FAC
Control

75
70

38
28

.02
.02

41
26

.02
.02

*p values were one-tailed test
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Summary of Estimated Disease-Free Survival at 5 Years by
Estrogen Receptor Status and Maintenance Treatment of
Third Study

MV
TMV
T
Patient
Percent
Percent
Percent
CharacterPts. Disease-Free Pts. Disease-Free Pts. Disease-Free
istics
Total

122

66

113

73

90
32

67
65

76
37

81
53

101

64

ER
Positive
Unknown

= estrogen receptor status
T = patients receiving tamoxifen
TMV = patients receiving tamoxifen, methotrexate, and vinblastine
MV = patients receiving methotrexate and vinblastine

ER

The Importance of ER Status
With regard to the ER status of patients in these studies,
Buzdar points out that similar observations have been reported
by other investigators: in spite of adjuvant chemotherapy,
patients with ER-negative tumors had inferior disease-free survival rates compared with the rates in patients with ER-positive
tumors. Because ER-negative patients usually have more aggressive disease, they tend to do poorly in comparison with ERpositive patients .

continued on page 8
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Diagnostic Radiologists Use Expandable Metallic
Sten ts for Sytnptotn Relief in Selected Patients
A growing number of diagnostic
radiologists are shifting the focus of
their practice toward intervention.
Interventional radiologists use vari,
ous methods-for instance, direct
chemotherapy to the tumor or block,
ing of the tumor's blood supplyto treat tumors that are too far ad,
vanced for resection but confined to
a local area. T heir main goal may not
be to cure th e cancer but to relieve
the patient's symptoms and "get
h im in shape" for further radio, or
chemotherapy or surgery. Cesare
Gianturco, M .D., an adjunct profes,
sor in the D epartment of Diagnostic
Radiology at The University of Texas
M . D. Anderson Hospital and Tumor
Institute at Houston, develops med,
ic al inst ru ments with this aim
in mind.

Older Procedures
Problematic

Fig. 1. The Gianturco expandable metallic stent.

Cesare Gianturco

Chusi/p Charnsangavej

In the past, angioplasty or balloon dilatation has been
employed to open tubular structures occluded by fibrosis or
tumor. These procedures were problematic, however, because
often after treatment the vessel would close again. Furthermore,
surgery was required to rebuild the vessels. To combat these
problems, in 1984 Gianturco invented the expandable metallic
stent, a wire frame that bypasses or opens collapsed vessels and
closed passages and then keeps them open.
The Gianturco stent (Figure 1) is made of stainless steel wire
0.0375 to 0.045 cm in diameter. The wire is first bent in a zigzag,
and then its two ends are attached to one another, forming a
cylindrical frame 2.5 to 3 cm in diameter. An extra wire, or barb,
is soldered to the stent to prevent its migration. Depending on
the length of wire used, the larger is the angle of the zigzags, the
greater the diameter of the stent, and the stronger its expansile
force. The stents are usually 2 to 3 cm long, but if a longer pas,
sageway is needed, two or more stents can be connected to one
another with a wire strut, forming a double or longer stent and
spreading the expansile force without weakening it. Double
stents also have barbs to keep them in place.
The stent is placed in the patient's vein through a percutaneous
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catheter. First the frame is compressed and slipped into the cathe,
ter tube. Then the catheter is inserted normally into the vein in
which the stent is to be placed. The stent is pushed out of the
catheter into the vessel, where it expands, with an instrument
called an introducer; the introducer holds the stent in place at
the tip of the catheter while the catheter is withdrawn until the
stent is released into the vessel. Since percutaneous placement
is not a surgical procedure, the patient requires only a local anes,
thetic. If the stent is to be placed in a patient's tracheo, bronchial
tree, the same procedure is followed, but a bronchoscope is used
instead of a catheter.

Initial Tests Showed Promise
The expandable metallic stents were initially tested in 1984 at
The University of Texas System Cancer Center in experimental
animals. The stents were placed in normal vessels first to gauge
tissue reactions. Since the results of those experiments were
encouraging, Chusilp Charnsangavej, M.D., and Sidney
Wallace, M.D., of the Department of Diagnostic Radiology at
UT MDAH, used five single stents to treat a patient for supe,
rior vena cava syndrome and myocutaneous graft collapse
in the tracheobronchial tree. The patient experienced immedi,
ate symptom relief, although she died three weeks later of
myelosuppression.
Expandable metallic stents have been placed in 10 patients so
far to treat stenosis of the superior vena cava or blockage of
the tracheobronchial tree, and the results have been good in ·
every case but one, a patient with mediastinal osteogenic sar,
coma metastases wrapping around the tracheobronchial tree.
"The tumor was too hard to open up," Charnsangavej laments.
In no case, however, have the stents caused clotting or thrombo,
sis; in fact, new epithelium formed around every stent in the vena
cavae, and mucosal secretions covered every stent in the tracheo,

continued on page 6
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bronchial trees. Charnsangavej speculates that the continual
flow of blood over the stent is what keeps the vessels from devel,
oping thromboses.
Gianturco fashioned all of the first expandable metallic stents
himself. He continues to make most of them now, but some labo,
ratory technicians also build them. Charnsangavej expects that
Cook, Inc., in Bloomington, Indiana, will eventually acquire the
patent for the Gianturco stent.

Use in Humans Still Experimental
Until the United States Food and Drug Administration sane,
tions the Gianturco stent, only physicians at UT MDAH may
use it, under conditions approved by the UT MDAH Surveil,
lance Committee. The FDA requires years of testing before
it endorses a new product such as this one. Stents similar to
Gianturco's are currently being utilized in Europe; by doctors in
Portland, Oregon; and at Shadyside Hospital in Pittsburgh,
Pennsylvania.
Expandable metallic stents have also been tested, with favor,
able results, in the bile ducts of dogs at the UT System Cancer
Center, but they are not used in the bile ducts of patients here
yet. Some physicians in Europe are placing such stents in human

bile ducts, and they report positive results. At least four other
groups are also interested in employing the Gianturco stents to
treat bile duct occlusions.
Researchers are now endeavoring to develop a stent similar to
Gianturco's for use in arteries. Because arterial stents employ a
balloon as well as the wire frame, they are called "balloon,
assisted" expandable metallic graft stents. Gianturco himself is
testing such a stent in dog arteries at UT MDAH. Arterial stents
are also being tested in the coronary arteries of dogs at Emory
University.
Despite the success of the Gianturco stent, many questions
remain. For instance, does the stent cause late complications?
Although no late complications have been noted yet, the longest
survival time so far is still only 6 months. How much expansile
force does the stent need to exert? Too much force could cause the
stent to perforate the structure, whereas too little force could
keep the stent from making the tube patent. Can the extrinsic
force that the stent must combat be measured? More experimen,
tation is needed to answer these questions and confirm the good
results seen up to now.

Physicians who desire additional information may write Chusilp
Charnsangavej, M.D., Department of Diagnostic Radiology, Box 57,
The University of Texas M. D. Anderson Hospital and Tumor lnsti,
tute at Houston, 1515 Holcombe Boulevard, Houston, Texas 77030.

Nutritional and Psychological Aspects of
Feeding Children Who Have Cancer
by Cheryl Mokrzecky,
M.S., R.D., L.D.
Dietitian
Nutrition and Food Service

Nutritional Assessment

At UT MDAH, nutritional status is assessed by a nutrition
history and a combination of anthropometric and biochemical
measures. Weight and height measurements, serum albumin lev,
Because children with cancer are
els, and a determination of current food intake are used for initial
developing and maturing through,
screening. For children, the primary anthropometric measure,
out their illness and treatment, their
ment is the ratio of weight to height, a measurement that relates
~unmomrl 11eeds arc:quite--differen·r ---+--+---------l:------ - -----t-- -----n-o-dy1nass-to~e~--his-measurerrrerrt is corr1parerr,-orrgrowtl1
from those of healthy children and
grids, to standards developed by the National Center for Health
adults. Moreover, malnutrition at a
Statistics (NCHS) for a reference population. Age is plotted
time of rapid growth can cause physi,
along the axis, and height or weight values are plotted along the
cal and intellectual delays in develop, Cheryl Mokrzecky
abcissa. This shows how children rank in size in relation to other
ment as well as behavioral changes. The major factors that con,
children of the same age and sex.
tribute to malnutrition in children with cancer are related to the
In our hospital, the dietitian uses the following weighHo,
disease, the side effects of treatment, and psychological factors
height percentage formula to identify patients at nutritional risk:
such as family stress. Dietitians at UT M. D. Anderson Hospital
Weight % = Patient's weight X _,
100
(UT MDAH) work with patients and families to maintain op,
timum nutritional status, growth, and development in the child.
Height
Patient's height
s
continued on page 7
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where S

= NCHS 50th percentile weight for age
N CHS 50th percentile height for age

Patients whose weighMo-height percentage is less than 90%,
according to this formula, are considered at risk for malnutrition
(Donaldson SS, Wesley WN, De Wys W, et al: A study of the
nutritional status of pediatric patients. Am J Dis Child, in press).
However, interpretation of a child's growth is best when
observed over a period of time rather than from a single measurement. Malnutrition should be suspected in any child who does
not grow properly.
Dietary evaluation, which is an important adjunct to clinical
and biochemical assessment, provides information about the
patient's current level of nutrient intake and family eating patterns. It includes a nutrition history and food frequency determinations, as well as information about the use of nutritional or
vitamin supplements, vegetarianism, or other dietary practices
that may suggest potential nutritional problems.
There is no single biological parameter to assess nutritional status, but dietitians at UT MDAH use measurement of serum
albumin to evaluate the adequacy of a patient's protein status.
Hypoalbuminemia may be an indicator of malnutrition.
Patients who exhibit abnormalities in one or more nutritional
parameters should be monitored frequently during treatment.
Awareness of the fact that some tumors profoundly affect nutritional status can aid in identifying patients who require early
nutritional intervention.
The incidence of malnutrition in patients with cancer tends to
be highest in children who have advanced or metastatic disease.
Moreover, children who are diagnosed with Ewing's sarcoma or
neuroblastoma are at great risk for malnutrition. Adolescents, in
general, may be at a high risk for malnutrition due to their
increased metabolic requirements.

Effects of Cancer and Cancer Treatment
Most children with cancer undergo chemotherapy as their primary treatment. The agents used may produce severe gastrointestinal side effects such as nausea, vomiting, diarrhea, mucositis,
and dysgeusia. During chemotherapy administration, children
should be encouraged to take clear liquids such as gelatin desserts, broth, clear frozen desserts, and carbonated beverages,
since these are usually well-tolerated on a queasy stomach. Fluids
with electrolytes should be given to replace body fluids lost
because of vomiting and diarrhea. Eating dry foods such as
crackers or toast may help alleviate the feeling of nausea.
The corticosteroid hormones, used alone or in combination
with chemotherapy, also have adverse nutritional effects. These
agents increase catabolism of lean body mass. Patients may have
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difficulty in meeting the increased protein and calorie needs associated with these agents, even though their appetites may
increase. Finally, the fluid and electrolyte disturbances accompanying steroid administration may cause edema that masks the
loss of lean body mass.

Eating Disorders
A child's eating may also be affected by less obvious factors
such as family stress, depression, or a struggle for control within
the family.
When a child has cancer, the family's normal routine is disrupted in many ways. Parents often have to function separately,
since one parent may continue to work and care for siblings at
home while the other parent stays with the sick child in the hospital. The stress imposed by this situation may magnify problems
that existed before the child's illness.
Families often participate in a child's health care by feeding the
child. Since weight loss and cachexia represent illness and normal growth signifies health, parents may become preoccupied
with their child's eating. Extreme concern about a child's weight
may mask the parent's fear that the child will die. If the child's
normal eating pattern is disrupted, the parent often feels hopeless, having lost influence in an activity that he or she had been
able to control before the child's illness. As the parent experiences a sense of failure, efforts to force the child to eat increase.
Unfortunately, the focus on eating may actually depress the
child's appetite and food intake.
Struggles for control in pediatric patients, especially in adolescents, may be manifested in eating disorders. Children with cancer sometimes develop anorexia nervosa in a subconscious
attempt to reduce their feelings of dependence and loss of freedom and individuality. Some patients use eating as a way to gain
attention from their parents.

Nutritional Support During Therapy
Nutritional support using oral supplements, tube feedings, or
parenteral nutrition can prevent weight loss and aid in maintaining or regaining nutritional status.
Meeting the nutritional needs of anorectic children with adequate quantities of nourishing food can be a challenge. If a child
has one or more of the following problems, he or she may need
nutritional supplementation:
1. Arrest in expected weight gain
2. Evidence of malnutrition as indicated by abnormal
biochemical parameters
3. Difficulty chewing or swallowing food
4. Persistent nausea and vomiting
5. Inadequate dietary intake

continued on page 8
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Conclusions
Currently at UT MDAH, Buzdar and his colleagues are evaluating the role of high-dose intensification with autologous bone
marrow support in patients with metastatic disease. Patients are
initially treated with doxorubicin combinations (FAC). After
two or three cycles of chemotherapy, patients who show a complete or partial response have their bone marrow extracted and
stored. These patients are treated with an additional few cycles of
the FAC regimen and high-dose chemotherapy with bone marrow support. This study is currently ongoing and is being conducted with UT MDAH's bone marrow transplant team.
Patients with stage II and III disease are currently being entered
in a prospective study comparing the efficacy of tamoxifen
administration for five years with the FAC regimen. In stage I
patients (with negative nodes) they are evaluating four cycles of
doxorubicin chemotherapy compared with no further treatment
after local therapy.

Physicians who desire additional information may write Aman U.
Buzdar, M.D., Department of Medical Oncology, Box 78, The
University of Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 1515 Holcombe Boulevard, Houston, Texas 77030.

Feeding Children Who Have Cancer ...
continued from page 7
High-protein, high-calorie foods such as peanut butter, nuts,
cheeses, milkshakes, instant breakfast, or nutritional supplements can provide concentrated sources of nutrients. Small, frequent feedings may be more effective in increasing total intake.
Acceptance of nutritional supplements may depend on the
patient's taste perception. The senses of taste and smell may be
affected by treatment, and foods that children enjoyed prior to
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treatment may lose their appeal or taste bad. Children then associate those foods with the side effects of treatment and avoid
them. These are called learned food aversions. In view of this
phenomenon, dietitians at UTMDAH frequently encourage
children to consume their favorite foods only while they are feeling well.
When all efforts to support a child's nutritional status through
the oral route have failed, nutrition via the enteral route is the
preferred method of feeding, if the gastrointestinal tract is functional. When compared to parenteral nutrition, enteral feedings
have a lower risk of complications and are less expensive. Tube
feedings given during the night and discontinued during the day
can allow the child to carry on normal daily activities. Tube feeding formulas for children over two years of age can be chosen
from the enteral products for adults. Intolerance to a tube feeding may be manifested by nausea, vomiting, diarrhea, abdominal
cramping, or bloating. These can usually be alleviated by adjusting the rate or the strength of the feeding; however, continued
intolerance may require a change in formula. Feedings may be
administered as a continuous infusion by a pump or as bolus
feedings given over a period of 20-30 minutes.
Parenteral nutrition may be given to replenish or maintain
nutritional status when the gastrointestinal tract is dysfunctional. However, arenteral nutrition is more costly and re uires
more complex monitoring than enteral feeding.
Providing aggressive nutritional support as soon as nutritional
deterioration is detected or anticipated can prevent malnutrition. It is much easier to minimize or prevent malnutrition than
to reverse a severely malnourished state. Children who are able
to maintain adequate nutrition throughout their therapy feel
better, have fewer complications, and are able to continue chemotherapy with fewer delays (van Eys J, Cancer Res, 1982;
42(Suppl): 74 75-7515).

Physicians who desire additional information may write Nutrition
and Food Service, Box 58, The University of Texas M. D. Anderson
Hospital and Tumor Institute at Houston, 1515 Holcombe Boulevard,
Houston, Texas 77030.
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